[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational …
Objectives This study aimed to evaluate the efficacy and adverse events of favipiravir in
patients with COVID-19. Methods Our protocol was registered on PROSPERO …
patients with COVID-19. Methods Our protocol was registered on PROSPERO …
Favipiravir in patients with early mild-to-moderate coronavirus disease 2019 (COVID-19): a randomized controlled trial
Y Golan, JAS Campos, R Woolson… - Clinical Infectious …, 2023 - academic.oup.com
Background Despite vaccination, many remain vulnerable to coronavirus disease 2019
(COVID-19) and its complications. Oral antivirals to prevent COVID-19 progression are vital …
(COVID-19) and its complications. Oral antivirals to prevent COVID-19 progression are vital …
[HTML][HTML] Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial
Background Well tolerated antivirals administered early in the course of COVID-19 infection
when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits …
when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits …
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study
R Sirijatuphat, W Manosuthi… - Emerging Microbes & …, 2022 - Taylor & Francis
We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia
and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia …
and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia …
[HTML][HTML] Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2× 2 factorial placebo-controlled trial of early antiviral therapy in …
Background Early antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19)
but currently available agents are expensive. Favipiravir is routinely used in many countries …
but currently available agents are expensive. Favipiravir is routinely used in many countries …
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study
Background: The great majority of severe acute respiratory syndrome-related coronavirus 2
(SARS-CoV-2) infections are mild and uncomplicated, but some individuals with initially mild …
(SARS-CoV-2) infections are mild and uncomplicated, but some individuals with initially mild …
[HTML][HTML] Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
V Luvira, WHK Schilling, P Jittamala, JA Watson… - BMC Infectious …, 2024 - Springer
Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro …
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro …
[HTML][HTML] Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma
E Challenger, SD Penchala, C Hale… - … of pharmaceutical and …, 2023 - Elsevier
Favipiravir (FVP) is a broad-spectrum antiviral that selectively inhibits viral RNA-dependent
RNA polymerase, first trialled for the treatment of influenza infection. It has been shown to be …
RNA polymerase, first trialled for the treatment of influenza infection. It has been shown to be …
[HTML][HTML] A clinical insight on new discovered molecules and repurposed drugs for the treatment of COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began churning out
incredulous terror in December 2019. Within several months from its first detection in …
incredulous terror in December 2019. Within several months from its first detection in …